Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) represented a move of 0 percent or $0.45 per share and closed its previous day trading session at $4.94. 0 Shares were traded in the last trading session with an Average Volume of 358.53 Million Shares. The stock currently has a Market Capitalization of 125.83 Million.
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company’s product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.
The stock traded between $ 4.36 and $15.20 over 1-Year time period showing its price to sales ratio of 54.71. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-17.57 and 200-Day Simple Moving Average of $-40.41. Its Price to Free Cash Flow is 0 and Price to Book of 1.96.
Analyst’s recommended the stock as 1.9 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) reported its Actual EPS of $-0.68/share. The analysts offering Earnings Estimates for the company were believing that Syndax Pharmaceuticals, Inc. could bring EPS of $-0.76/share. The difference between Actual EPS and Estimated EPS was 0.08 Percent. Thus showing an Earnings Surprise of 10.5 Percent.
China Pharma Holdings, Inc. (NYSE:CPHI)
In the last trading session, China Pharma Holdings, Inc. (NYSE:CPHI) added its value by 0% closing at the price of $0.28. The stock currently has market capitalization of 12.3 Million, with average volume of 1.06 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently China Pharma Holdings, Inc. (NYSE:CPHI) is showing beta of 1.29. This particular value of beta suggests that China Pharma Holdings, Inc. (NYSE:CPHI) has historically moved 129% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for China Pharma Holdings, Inc. (NYSE:CPHI) is at $-0.39.
The stock currently has RSI of 43.03. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings.
China Pharma Holdings, Inc. (NYSE:CPHI) topped its 52-week high price of $1.450 on 01/05/18 and 52-Week Low Price of $0.160 on 12/07/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 10.18% and monthly volatility of 11.38% respectively.